Balversa (erdafitinib) — CareFirst (Caremark)
Biliary tract cancers (cholangiocarcinoma)
Initial criteria
- Diagnosis of intrahepatic or extrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements
- Used as a single agent
- Used as subsequent therapy for unresectable, resected gross residual (R2), or metastatic disease
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months